Patent intelligence · US
US 11339169
P2X3 and/or P2X2/3 compounds and methods
P2X3 and/or P2X2/3 compounds and methods
Patent details — US 11339169
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 24, 2022
- Expiration
- May 19, 2042
- Applicant
- Asana BioSciences, LLC
- Claims
- 39
- CPC classes
- A61P, A61P11/00, A61P11/06, A61P11/08
Quick answer
US 11339169 (P2X3 and/or P2X2/3 compounds and methods) is held by Asana BioSciences, LLC. Status: granted. Granted May 24, 2022. Expires May 19, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Asana BioSciences, LLC
- Grant date
- Expiration
- Claims
- 39
- CPC classes
- A61P, A61P11/00, A61P11/06, A61P11/08, A61P25/00, A61P25/04
More from Asana BioSciences, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12427199
Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
granted -
US 12409213
Live attenuated oral vaccine against shigellosis and typhoid fever
granted -
US 12246059
Stable hybrid FC fusion G-CSF formulation
granted -
US 12171822
Infectious plasmodium sporozoites grown in vitro
granted -
US 12156870
Antibody drug conjugates comprising sting agonists
granted -
US 12129288
Polynucleotides heterodimers of soluble interferon receptors and uses thereof
granted -
US 12077543
P2X3 and/or P2X2/3 compounds and methods
granted -
US 11987628
Methods and compositions for modulating CAR-T activity
granted
Frequently asked questions
What is US patent 11339169?
US 11339169 (P2X3 and/or P2X2/3 compounds and methods) is held by Asana BioSciences, LLC. Status: granted. Granted May 24, 2022. Expires May 19, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11339169?
Asana BioSciences, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 136 pharmaceutical patents for this assignee.
When does US 11339169 expire?
Our index shows an expiration date of May 19, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.